Ipsen Management
Management criteria checks 2/4
Ipsen's CEO is David Loew, appointed in Jul 2020, has a tenure of 6.17 years. total yearly compensation is €10.42M, comprised of 9.8% salary and 90.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €13.78M. The average tenure of the management team and the board of directors is 4.1 years and 11.3 years respectively.
Key information
David Loew
Chief executive officer
€10.4m
Total compensation
| CEO salary percentage | 9.84% |
| CEO tenure | 6.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.1yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
Narrative Update • Sep 03
IPN: Oncology And Rare Disease Pipeline Will Offset Emerging Somatuline Competition Risks
The analyst price target for Ipsen has shifted to €167.07 from €161.67 as analysts balance Jefferies' downgrade on Somatuline competition risk with H.C. Wainwright's higher €235 target, which is linked to the Kartos acquisition and the perceived strength of Ipsen's oncology and rare liver disease portfolio. Analyst Commentary Analysts are split on Ipsen, with some focusing on growth from oncology and rare liver disease assets and others paying close attention to competitive risks around Somatuline.
Narrative Update • Aug 18
IPN: Somatuline Competition And Execution Risks Will Limit Future Share Upside
Analysts have updated the Ipsen fair value estimate from €117.00 to €130.00. This reflects a range of recent research views that balance concerns about potential Somatuline competition with more positive expectations around the Kartos acquisition and the broader specialty portfolio.Narrative Update • Aug 03
IPN: Oncology And Rare Disease Pipeline Offsets Somatuline Competition Concerns
Analysts have nudged Ipsen's fair value estimate higher to about €161.67 from €159.25, balancing concerns about competitive pressure on Somatuline with support from recent price target increases related to the Kartos acquisition and a stronger view of the broader portfolio. Analyst Commentary Recent research on Ipsen shows a split between bullish analysts who focus on portfolio strength and deal execution, and bearish analysts who focus on competitive risks around Somatuline and how that could affect long term growth assumptions.
Narrative Update • Jul 13
IPN: Rare Disease And Oncology Acquisitions Will Drive Re Rated Earnings Potential
The updated analyst price target for Ipsen reflects a modest fair value revision from approximately €211 to €218, supported by recent target increases and positive commentary on the acquired Kartos asset and the strength of the rare liver disease portfolio. Analyst Commentary Recent research on Ipsen highlights a cluster of upbeat views, with several bullish analysts adjusting their valuation frameworks after reviewing the acquired Kartos asset and the rare liver disease portfolio.Narrative Update • Jun 29
IPN: Rare Liver Disease And Oncology Portfolio Will Drive Re Rated Earnings Potential
The analyst price target for Ipsen has shifted from €183 to about €211. Analysts point to the company's oncology portfolio, rare liver disease products, and neuroscience offering as the main reasons for the higher valuation assumptions.Narrative Update • Jun 15
IPN: Oncology And Rare Liver Pipeline Progress Will Shape Balanced Future Outlook
The analyst price target for Ipsen has been raised from €151.94 to €159.25. Analysts cite the company's oncology, rare liver disease and neuroscience portfolio, along with profit margin assumptions and P/E expectations, to justify the change.Narrative Update • Jun 01
IPN: Oncology Safety Concerns And Pipeline Uncertainty Will Limit Future Share Upside
Analysts have lifted the Ipsen fair value estimate from €115 to €117, citing higher modeled revenue growth and slightly stronger profit margins, while Street price targets from banks including Deutsche Bank, JPMorgan and BNP Paribas continue to reset higher despite the recent tazemetostat withdrawal. Analyst Commentary Street research signals a mixed picture for Ipsen, with several large banks lifting their price targets while others highlight risks around the tazemetostat withdrawal and future growth execution.Narrative Update • May 17
IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential
Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.Narrative Update • Apr 24
IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential
Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.Narrative Update • Apr 10
IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook
Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.Narrative Update • Mar 27
IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside
The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.Narrative Update • Mar 13
IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside
The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.Narrative Update • Feb 27
IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential
The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.Narrative Update • Feb 12
IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook
Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.Narrative Update • Jan 29
IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook
Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.Narrative Update • Jan 15
IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook
Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.Narrative Update • Dec 21
IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook
Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.Narrative Update • Dec 07
IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook
Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.Narrative Update • Nov 22
IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook
Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.Narrative Update • Nov 07
IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.Analysis Article • Oct 28
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Oct 24
Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.Narrative Update • Sep 25
Pipeline Catalysts And Approvals Will Expand Global Access
Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.
New Narrative • Feb 23
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | €513m |
| Mar 31 2026 | n/a | n/a | €478m |
| Dec 31 2025 | €10m | €1m | €444m |
| Sep 30 2025 | n/a | n/a | €446m |
| Jun 30 2025 | n/a | n/a | €448m |
| Mar 31 2025 | n/a | n/a | €402m |
| Dec 31 2024 | €5m | €1m | €356m |
| Jun 30 2024 | n/a | n/a | €664m |
| Mar 31 2024 | n/a | n/a | €641m |
| Dec 31 2023 | €4m | €988k | €617m |
| Jun 30 2023 | n/a | n/a | €406m |
| Mar 31 2023 | n/a | n/a | €500m |
| Dec 31 2022 | €4m | €950k | €593m |
| Sep 30 2022 | n/a | n/a | €656m |
| Jun 30 2022 | n/a | n/a | €719m |
| Mar 31 2022 | n/a | n/a | €675m |
| Dec 31 2021 | €5m | €950k | €631m |
| Sep 30 2021 | n/a | n/a | €626m |
| Jun 30 2021 | n/a | n/a | €622m |
| Mar 31 2021 | n/a | n/a | €585m |
| Dec 31 2020 | €5m | €475k | €548m |
Compensation vs Market: David's total compensation ($USD12.11M) is above average for companies of similar size in the French market ($USD5.64M).
Compensation vs Earnings: David's compensation has increased by more than 20% in the past year.
CEO
David Loew (59 yo)
6.2yrs
Tenure
€10,417,318
Compensation
Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020 and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 6.2yrs | €10.42m | 0.11% € 13.8m | |
| Executive VP & CFO | 11.8yrs | €1.02m | no data | |
| Executive VP & Head of Technical Operations | less than a year | no data | no data | |
| Global Vice President of Investor Relations | no data | no data | no data | |
| Executive VP & General Counsel | 1yr | no data | no data | |
| Head of Global Media Relations | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | 8.5yrs | no data | no data | |
| Executive VP & Chief Business Officer | 5.9yrs | no data | no data | |
| Executive VP | 4.8yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 3.3yrs | no data | no data | |
| Executive VP and Head of R&D | 3yrs | no data | no data | |
| Executive VP & Chief Corporate Affairs Officer | 2.1yrs | no data | no data |
4.1yrs
Average Tenure
57yo
Average Age
Experienced Management: IPN's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 6.3yrs | €10.42m | 0.11% € 13.8m | |
| Non-Executive Chairman | 15.8yrs | €600.00k | 0.16% € 21.4m | |
| Independent Director | 9.3yrs | €170.00k | 0.00084% € 109.2k | |
| Director | 11.3yrs | €110.95k | 0.00061% € 79.3k | |
| Vice Chairman | 21.1yrs | €189.32k | 0.0037% € 475.6k | |
| Director | 21.1yrs | €60.00k | 26.61% € 3.5b | |
| Independent Director | no data | €135.00k | no data | |
| Director | 14.3yrs | €170.35k | 0.00061% € 79.3k | |
| Director | 14.7yrs | €155.00k | no data | |
| Independent Director | less than a year | no data | no data | |
| Employees Representative Director | 5.8yrs | no data | 0.0016% € 213.1k | |
| Employee Representative Director | 4.3yrs | no data | 0.0042% € 547.1k |
11.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: IPN's board of directors are seasoned and experienced ( 11.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 18:02 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipsen S.A. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Charles Pitman | Barclays |
| Yihan Li | Barclays |